Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma.

Gerda M VerduijnSteven F PetitIris LauwersYvette van NordenNienke D SijtsemaAniel SewnaikHetty MastMarta CapalaRemi A NoutSarah BakerEsther van MeertenMischa S HoogemanAad van der LugtWilma D Heemsbergen

Published in: Acta oncologica (Stockholm, Sweden) (2022)

The risk of PRMU should be included in the cost benefit analysis when considering future research using a hypofractionated SBRT boost for OPSCC patients.

Keyphrases

radiation therapy
brain metastases
end stage renal disease
newly diagnosed
radiation induced
small cell lung cancer
prognostic factors
locally advanced